Teva Pharmaceutical Industries (NYSE:TEVA) Reaches New 12-Month High - Time to Buy?

Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Get Free Report) reached a new 52-week high on Monday . The stock traded as high as $22.17 and last traded at $22.16, with a volume of 5554103 shares traded. The stock had previously closed at $22.09.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on TEVA shares. JPMorgan Chase & Co. raised their target price on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a "neutral" rating in a research report on Monday, October 21st. UBS Group lifted their price objective on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a "buy" rating in a research report on Tuesday, September 3rd. Barclays boosted their target price on shares of Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the company an "overweight" rating in a research note on Wednesday, December 18th. Finally, StockNews.com lowered shares of Teva Pharmaceutical Industries from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, December 18th. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $20.88.

Teva Pharmaceutical Industries Price Performance

The firm has a market cap of $25.16 billion, a P/E ratio of -26.13, a PEG ratio of 0.99 and a beta of 0.79. The business's fifty day simple moving average is $17.89 and its 200-day simple moving average is $17.56. The company has a current ratio of 0.89, a quick ratio of 0.61 and a debt-to-equity ratio of 2.57.

Insider Buying and Selling

In related news, EVP Christine Fox sold 19,388 shares of the business's stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total transaction of $327,075.56. Following the completion of the transaction, the executive vice president now owns 44,104 shares of the company's stock, valued at approximately $744,034.48. The trade was a 30.54 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.55% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of TEVA. FMR LLC boosted its position in shares of Teva Pharmaceutical Industries by 49.5% during the 3rd quarter. FMR LLC now owns 62,740,763 shares of the company's stock valued at $1,130,589,000 after acquiring an additional 20,762,226 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd lifted its position in Teva Pharmaceutical Industries by 6.8% during the third quarter. Clal Insurance Enterprises Holdings Ltd now owns 34,543,812 shares of the company's stock valued at $621,337,000 after purchasing an additional 2,204,623 shares during the last quarter. State Street Corp grew its stake in Teva Pharmaceutical Industries by 10.0% in the 3rd quarter. State Street Corp now owns 19,500,683 shares of the company's stock worth $351,402,000 after buying an additional 1,778,268 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Teva Pharmaceutical Industries by 3.4% in the 3rd quarter. Geode Capital Management LLC now owns 8,792,011 shares of the company's stock worth $157,571,000 after buying an additional 291,124 shares during the last quarter. Finally, Renaissance Technologies LLC increased its holdings in shares of Teva Pharmaceutical Industries by 13.4% in the 2nd quarter. Renaissance Technologies LLC now owns 8,728,563 shares of the company's stock worth $141,839,000 after buying an additional 1,031,400 shares during the last quarter. 54.05% of the stock is owned by institutional investors.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.